Popular topics to explore
16 hours ago · SEBI Registration INH000016843
SEBI Registration INH000016843 · 16 hours ago
“Why Confirmation Improves Trade Quality”
A price level may look attractive, but entering immediately does not always provide a high-quality trade. Confirmation helps traders understand whether buyers or sellers are actually responding around an important area. This can reduce the…
Glenmark Launches Ryaltris in Brazil for Rhinitis
GLENMARK has expanded its global respiratory innovation footprint with the launch of Ryaltris in Brazil. The introduction marks the entry of the company’s differentiated dual-action therapy for allergic rhinitis into the Brazilian market.…
Govt Plans Central Licensing for Sterile Drug Makers
The government plans to bring all sterile drug products under a central licensing system to tighten oversight following quality lapses. Around 240 injection samples were found not of standard quality in FY26, prompting the move to shift lic…
“Why Patience Improves Trade Selection” ..
The market is continuously moving, but that does not mean every movement deserves a trading position. One of the most important skills in trading is knowing when the conditions are incomplete and waiting for the setup to develop. Impatient…
Cipla Expands Oncology Portfolio with Key ADC Deal
CIPLA
Cipla is in focus after entering into an exclusive licensing and supply agreement with Sino Biopharmaceutical’s subsidiary CTTQ for TQB2102, a HER2-targeted bispecific antibody-drug conjugate (ADC). The deal gives Cipla rights to de…
Cipla Weakens as Momentum Slips Below Trend Support
CIPLA remains one of the stronger quality franchises within Indian pharma, with a diversified presence across domestic formulations, respiratory therapies and international markets. The broader pharmaceutical space continues to benefit fr…
Cipla — The Respiratory Leader Is Building Its Next Engine
CIPLA
Respiratory is growing. Chronic therapies are expanding. India is scaling. And Cipla is steadily turning its strong domestic franchise into a broader healthcare growth story.
Cipla is no longer just a traditional pharma company.
I…
“Why Emotional Decisions Can Damage a Good Trading System”
A well-defined trading system can lose its effectiveness when the trader stops following its rules. Emotional decisions often appear after a significant win, a series of losses, or a missed opportunity. The trader may increase position size…
Indian Markets Flat | FIIs Selling 📉 | DIIs Absorb
HINDCOPPER 📊 Indian Market Opening Snapshot
GIFT Nifty: ~24,180–24,200 → flat-to-positive start.
Sensex (Prev Close): 77,420 (+0.31%).
Nifty 50 (Prev Close): 24,112 (+0.28%).
Bank Nifty (Prev Close): 57,890 (+0.42%).
🌍 Global & Comm…
Cipla Partners with Qilu for US Cancer Biosimilar
Research Analyst: UJVIN NEVATIA (PROPRIETOR: NEVAT INVESTMENTS) | SEBI Registration No.: INH100009628
Cipla ( CIPLA ), through its wholly owned subsidiary Invagen Pharmaceuticals Inc., has entered into an exclusive partnership with China-…
Cipla Expands US Biosimilar Oncology Portfolio
Cipla Ltd has entered into an exclusive US partnership with Qilu Pharmaceutical Co. Ltd through its wholly owned subsidiary Invagen Pharmaceuticals Inc. for QL2107, a biosimilar of Keytruda (pembrolizumab). Under the agreement, Qilu will…
Cipla shares ease after Keytruda biosimilar pact
CIPLA Shares of Cipla edged lower on Friday even after the company announced an exclusive US partnership for a biosimilar version of Merck’s blockbuster cancer drug Keytruda.
Cipla’s US subsidiary Invagen Pharmaceuticals signed a deal with…
Cipla Key U.S. Biosimilar Deal Amid Stock Weakness
Cipla ( CIPLA ) has a subsidiary, Invagen Pharmaceuticals Inc., that has entered into a strategic partnership with Qilu Pharmaceutical Co. for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda (pembrolizumab), in the U…
CIPLA EDGE LOWER AFTER KEYTRUDA PARTNERSHIP WITH QILU PHARMA
CIPLA
Cipla shares traded marginally lower on Friday despite strength in the broader market, following the drugmaker’s strategic partnership with China-based Qilu Pharmaceutical to develop and commercialise a biosimilar of Keytruda. The d…
Cipla Subsidiary InvaGen Signs Exclusive Deal
InvaGen Pharmaceuticals, a subsidiary of CIPLA, has entered into an exclusive agreement with Qilu Pharmaceutical for QL2107, a biosimilar of Keytruda. The agreement marks a strategic development for InvaGen in the biosimilar segment and ex…
Cipla: India Strength & Global Pharma Recovery
CIPLA Cipla remains a leading pharmaceutical company with strong franchises in respiratory, chronic therapies, generics and emerging markets. Q1 FY27 revenue rose 2.3% YoY to ₹7,119 crore, while PAT declined 39.2% to ₹789 crore, mainly due…
Cipla Expands Oncology Portfolio via TQB2102 Deal
Cipla Ltd has strengthened its oncology portfolio by entering into a licensing agreement with Chia Tai Tianqing Pharmaceutical (CTTQ), the Chinese arm of Sino Biopharma, for TQB2102, a HER2-targeted antibody-drug conjugate. Cipla will rec…
AUROBINDO PHARMA LAUNCHES GENERIC DRUG IN US
AUROPHARMA , through it's subsidiary Lannett Company, has launched generic Advair Diskus in the US, making it the first complex inhalation product by the company to be marketed there. This market is worth approximately $908 million. This l…
Cipla has entered into an licensing and supply agreement
Cipla has entered into an exclusive licensing and supply agreement with Sino Biopharmaceutical's subsidiary, Chia Tai Tianqing Pharmaceutical Group (CTTQ), for Rolditamig Deuderuxtecan (TQB2102). The deal brings a potential best-in-class o…
Kotak Bank, NCC & Cipla in Focus on Key Updates
KOTAKBANK : The bank has submitted Anup Saha and Rohan Kashyap as CEO candidates to the Reserve Bank of India (RBI). The development is important from a leadership and governance perspective as the bank moves through the process of selecti…
